One of Apple s Biggest Secrets behind their evaluation process of small acquisitions is revealed
People who have joined Apple through an acquisition and participated in the acquisition process told CNBC that Apple’s acquisition strategy focuses on getting talented technical staff from smaller companies, often valuing those companies in terms of the number of engineers working there, and quickly and quietly integrating them into teams at Apple.
Apple has used acquihires to speed expansion in fields where it needs technical talent or it sees a specific technology that could set it apart from its rivals. While the acquihire is a common technique among big tech companies, Apple’s near-exclusive focus on smaller transactions sets it apart.
How Apple does M&A: Small and quiet, with no bankers
CNBC 3 hrs ago Kif Leswing
In February, Apple CEO Tim Cook told shareholders that the company had bought about 100 companies in the past six years, which works out to the iPhone maker buying a company every three to four weeks.
Apple s strategy is to buy small small companies, often only employing a few people, primarily for their staff, who become employees at Apple.
Apple has gone on sprees picking up multiple firms in fields such as augmented and virtual reality, artificial intelligence, maps, health, and semiconductors, signaling an increased emphasis on those technologies.
Xencor begins dosing in Phase I trial of autoimmune disease treatment 29 Apr 2021 (Last Updated April 29th, 2021 17:28)
Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.
Share Article
The study will assess the safety, tolerability and pharmacokinetics of subcutaneously administered XmAb564 in healthy adult subjects. Credit: Edgar Y Pardo from Pixabay.
Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.
XmAb564 is a monovalent IL-2-Fc fusion protein that can selectively stimulate and expand regulatory T cells (Tregs) for treating autoimmune diseases.
信用負面周度回顧20210419-20210423 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Stem cell therapy can repair brain damage and improve memory function in mice
A one-time injection of an experimental stem cell therapy can repair brain damage and improve memory function in mice with conditions that replicate human strokes and dementia, a new UCLA study finds.
Dementia can arise from multiple conditions, and it is characterized by an array of symptoms including problems with memory, attention, communication and physical coordination. The two most common causes of dementia are Alzheimer s disease and white matter strokes -; small strokes that accumulate in the connecting areas of the brain. It s a vicious cycle: The two leading causes of dementia are almost always seen together and each one accelerates the other, said Dr. S. Thomas Carmichael, senior author of the study and interim director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.